The 5 Femtech Companies Investors are Actually Betting on Right Now
Cycle apps are out. Hard tech is in. The five companies that explain where the money is going.
Femtech is splitting in two.
On one side: the consumer apps and trackers that defined the category's first decade. Softer valuations, quieter rounds, unclear exits.
On the other: implantable devices, AI-native clinics, non-invasive diagnostics, hormonal hardware. Bigger checks. Real reimbursement strategies. Public-market ambition.
The split has been forming for two years. The past 90 days made it obvious. These are the five companies underneath it.
1. UroMems
$60M raised May 15 for UroActive, a smart implant for stress urinary incontinence.
SUI affects one in three women over 45. The current options are pelvic floor PT or surgical mesh — the latter with a black-box FDA history. UroMems is the non-mesh play, and investors are treating it as a category-defining bet.
UroMems closed within 48 hours of BlueWind Medical's $47.8M for urge incontinence and NinaMED's $13.75M launch for overactive bladder. Three pelvic health rounds in two days isn't coincidence — it's investors collectively pricing the category as a thesis.
Based in Grenoble, France.
2. Midi Health
$100M Series D in February, $1B+ valuation, led by Goodwater Capital. First menopause company to clear unicorn status.
Founder Joanna Strober built Midi after her own perimenopause diagnosis odyssey — multiple providers, a 45-minute drive out of San Francisco, $750 out of pocket. The pitch is that the same failures she experienced are happening to millions, and clinical telehealth with menopause-trained providers can capture the demand.
Midi's payer integration is the differentiator. Insurance acceptance in participating states makes the addressable market structurally larger than direct-pay competitors like Evernow and Alloy. The company is reportedly running at a $150M annual revenue rate — one of the highest in femtech.
3. Nourish
$100M Series C in May for an AI-native metabolic health clinic with full GLP-1 integration.
GLP-1 prescriptions have created an enormous parallel market for clinical support that legacy primary care can't handle. Nourish is positioned to capture it at scale, and women are the majority of the target population.
"AI-native" is the structural bet. AI handles workflow (intake, monitoring, escalation), licensed dietitians handle the clinical relationship. That staffing ratio is what makes the unit economics work at Series C scale.
4. BillionToOne
Launched Unity Confirm in May — a non-invasive prenatal test that captures and sequences intact circulating fetal cells from a maternal blood draw.
The current standard of care after a high-risk NIPT result is invasive confirmation (amniocentesis or CVS), both with small but real pregnancy-loss risk. Unity Confirm is the non-invasive bridge. At scale, it reshapes prenatal diagnostics — one of the largest reimbursed segments in women's health.
BillionToOne is already public (NASDAQ: BLLN). This isn't a Series C bet but a commercial product launch from a company operating at scale. For investors hunting public femtech comparables ahead of Oura's IPO, BillionToOne is the closest one that already exists.
5. Oura
Filed confidentially for a US IPO on May 21. Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co., Jefferies managing. $11B private valuation. Projected $2B in 2026 revenue.
Oura isn't a traditional femtech company. It's a consumer wearable that has spent the past 18 months building hormonal birth control support, menopause insights, and pregnancy tracking into Cycle Insights. The IPO is the first major public-market test for a women's-health-adjacent platform in years.
Consumer wearables trade at 3-5x revenue. Health-tech platforms with subscription economics trade at 8-12x or more. At Oura's projected $2B in revenue, that's the difference between a $6-10B and a $16-24B market cap. How Oura is priced will set the valuation precedent for Flo, Maven, Midi, Alloy, Kindbody, and Tia — all private, all watching.
The S-1 will reveal the rest.
What's missing, and why
No pure cycle-tracking apps. No symptom journals. No wellness content. No menopause-supplement DTC.
Rachel Braun Scherl, Managing Partner at SPARK Solutions for Growth, put it directly in FutureFemHealth's January expert roundup: "The most valuable women's health companies of 2026 won't be consumer apps but businesses solving unglamorous infrastructure problems."
The five above are the proof. Smart implants. Telehealth with payer integration. AI-augmented metabolic care. Non-invasive diagnostics. Hormonal hardware. Every one solves an unglamorous infrastructure problem at clinical depth.
The apps will still exist. They won't be the ones defining the category.
---
Sources: FemTech Insider (UroMems, BlueWind, NinaMED, Nourish, BillionToOne announcements, May 2026); Business Wire, Midi Health Series D announcement (February 2026); Bloomberg, Oura IPO filing (May 21, 2026); Horiva, Midi Health revenue analysis (March 2026); FutureFemHealth, "19 experts predict what's in store for FemTech and women's health in 2026" (January 2026); company announcements.